本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 编者按 在财富管理的大航海时代，私募基金以其灵活的策略、专业的团队和追求绝对收益的目标，吸引了越来越多高净值投资者的目光。然而，这个 行业也因其信息较少、不对称等特性，蒙上了一层神秘的面纱。策略如何运作？团队水平如何？短、中、长期业绩表现如何？风险控制究竟如 何......这些问题，往往是投资者在做出决策时，最难穿透的"迷雾"。正是基于此，私募排排网隆重推出 " 深度揭秘100家私募 " 栏目。为投资者 拨开云雾，提供真正有价值的深度洞察。 首期我们将揭秘 量化巨头幻方量化 ，该公司管理业绩和规模均位居国内前列。 下面，就让我们一起深入了解幻方量化。（ 点此看幻方量化旗 下基金业绩、核心团队、路演 ） （下期，你最想了解哪家私募？欢迎留言提名，呼声热度高的会优先推出！） | 幻方中证1000量化多策略2号 | 中证1000指增 | | --- | --- | | 九章幻方中证500量化多策略1号 | 中证500指增 | | 九章幻方中证500量化进取1号 | 中证500指增 | | 幻方量化信淮500指数专享19号7期 | 中证500指增 | | ...

Core Viewpoint - The A-share market experienced significant volatility in the first half of 2025, leading investors to prioritize the balance of returns and risks when selecting stock strategy products. The Sharpe ratio emerged as a crucial metric for evaluating risk-return profiles of these products [2]. Summary by Relevant Sections Overall Performance - In the first half of 2025, there were 2,891 stock strategy products with a displayed Sharpe ratio, achieving an average return of 12.4% and an average Sharpe ratio of 1.57. The products managed by private equity firms with a scale of 10-20 billion showed the highest average return at 16.39% [2][3]. Performance by Company Size - **100 Billion and Above**: - 420 products with a total scale of 632.37 billion, average return of 11.40%, and a Sharpe ratio of 2.03 [3]. - **50-100 Billion**: - 196 products with a total scale of 244.84 billion, average return of 12.12%, and a Sharpe ratio of 1.97 [3]. - **20-50 Billion**: - 258 products with a total scale of 267.26 billion, average return of 11.78%, and a Sharpe ratio of 1.85 [3]. - **10-20 Billion**: - 309 products with a total scale of 267.01 billion, average return of 16.39%, and a Sharpe ratio of 1.57 [3]. - **5-10 Billion**: - 422 products with a total scale of 250.14 billion, average return of 11.60%, and a Sharpe ratio of 1.50 [3]. - **0-5 Billion**: - 1,286 products with a total scale of 434.97 billion, average return of 12.19%, and a Sharpe ratio of 1.32 [3]. Top Products by Performance - The article highlights the top-performing stock strategy products across different company sizes, focusing on those with returns above the average and high Sharpe ratios. Notable products include: - **100 Billion and Above**: Quantitative long products dominated the top 10, with notable managers from Stable Investment and Wide De Private Equity [4][6]. - **50-100 Billion**: The top products were primarily subjective long and quantitative long strategies, with significant contributions from Qianyan Private Equity [8][10]. - **20-50 Billion**: Quantitative long products were most prevalent, with top managers from Jiuming Investment and Zhao Rong Hui Li Private Equity [13][15]. - **10-20 Billion**: A mix of subjective long products, with top managers from Xiangmu Asset and Haokun Shengfa Asset [18][21]. - **5-10 Billion**: Quantitative long products led the rankings, with top managers from Yangshi Asset and Zeyuan Investment [22][25]. - **0-5 Billion**: Quantitative long products were also prominent, with two products from Guangzhou Tianzhanhan making the top five [26][27].

Company Overview - Zhixin Rongke was established in 2013 by two core founders who previously worked at the renowned hedge fund company WorldQuant, focusing on strategy research as its core competitive advantage [2][6] - The company has developed a highly efficient investment research and trading system, accumulating a diverse range of strategies [2] Performance Highlights - Zhixin Rongke's quantitative CTA strategy has achieved good returns during weak market conditions (2022-2023) and demonstrated strong explosive potential in relatively strong years (2024-2025) [2] - As of May 2025, the "Zhixin Rongke Multi-Strategy No. 8 Class A" managed by Wu Zhengpeng has achieved a remarkable return of ***% over the past year, ranking first among the top ten quantitative CTA funds [2] Development Timeline - 2013: Company registration - 2016: Registration and filing - 2021: Initiated asset management business focusing on CTA strategies - 2023: Launched quantitative stock selection strategy - 2024: Completed upgrade of CTA strategy, adding stock index and treasury futures strategies - 2025: Launched mixed multi-strategy (quantitative CTA + stock selection strategy) and flexible hedging strategy [5] Core Team - The two founders hold PhDs from prestigious universities and have over ten years of quantitative trading experience, having worked as senior scientists at WorldQuant [6][7] Competitive Advantages - **Solid Foundation**: The founders' strong academic backgrounds and experience at WorldQuant contribute to a robust quantitative trading system, with a deep understanding of market dynamics [8] - **Rich Strategy Reserve and High Research Efficiency**: The company has developed a highly efficient backtesting and live trading system over more than a decade, resulting in a well-balanced and extensive strategy library [9] - **Complementary and Stable Core Team**: The founders' complementary expertise and clear division of labor have been crucial for maintaining long-term leadership in the industry [10] Product Lines - **Composite CTA Strategy**: The "Zhixin Rongke CTA No. 7 Class A" fund, established on June 8, 2021, consists of a combination of various low-correlation sub-strategies, covering over 50 futures products [12] - **Quantitative Stock Selection Strategy**: The "Zhixin Rongke Quantitative Stock Selection No. 1" fund, launched on October 14, 2022, employs a multi-factor strategy to select quality stocks while incorporating flexible hedging strategies [14] - **Mixed Multi-Strategy**: The "Zhixin Rongke Multi-Strategy No. 8 Class A" fund, established on September 8, 2022, combines 70% composite CTA strategy and 30% quantitative stock selection strategy to achieve stable overall returns [15]

Core Viewpoint - The private equity market in China has seen a significant increase in product registrations in the first half of 2025, driven primarily by a rebound in the A-share market and strong performance of quantitative strategies [2][4][5]. Group 1: Private Equity Product Registrations - A total of 5,461 private equity products were registered in the first half of 2025, marking a year-on-year increase of 53.61% and a month-on-month increase of 100.48% compared to the second half of 2024 [2]. - In June alone, 1,100 private equity securities products were registered, setting a new monthly record with a month-on-month growth of 26.44% [2]. - Stock strategies remained the dominant approach, accounting for 63.32% of the registered products, with 3,458 stock strategy products [2]. Group 2: Strategy Performance - Multi-asset strategies and futures/derivatives strategies followed stock strategies closely, with 802 and 633 products registered, representing 14.69% and 11.59% of the total, respectively [2]. - The performance of private equity securities products has been strong, particularly for quantitative strategies, which have attracted significant capital due to their superior excess return capabilities [4]. Group 3: Quantitative Strategies - Nearly 50% of the registered products in the first half of 2025 were quantitative, with 2,448 quantitative private equity products, reflecting a year-on-year increase of 67.10% [5]. - Among the quantitative products, stock strategies dominated with 1,715 products, making up 70.06% of the total quantitative products [5][6]. - The registration of futures and derivatives quantitative products reached 372, accounting for 15.20% of the quantitative total [5][6]. Group 4: Management Firms - A total of 1,775 private equity managers had registered products, with subjective private equity managers comprising 56.73% of the total [7]. - The number of small-scale private equity managers (0-10 billion) reached 1,371, representing 77.24% of the total [7]. - The top three quantitative private equity firms by product registration were Hei Yi Asset, Kuan De, and Beijing Zheng Ding, with 95, 79, and 62 products registered, respectively [8][9].

本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 私募排排网数据显示，有业绩显示的4166只私募产品中，2025上半年私募分红产品有558只，分 红占比为14.09%，上半年合计分红金额高达56.55亿元，这558只分红产品上半年收益均值为 13.43%，明显高于4166只的10.04%。 分私募规模来看，百亿私募中的59只分红产品，上半年实现分红约为15.59亿元，此外"小而 美"(0-5亿)私募旗下261只分红产品在上半年的分红金额约为11.99亿元，上半年收益均值高达 15.05%，表现较为突出。 | 公司规模 | 有分红的产品数 (分红次数) | 产品规模合计 (万元) | 下未在分红变额 (万元) | 上半年收益均值 | | --- | --- | --- | --- | --- | | 100亿以上 | રુ(୧૨) | 965137.83 | 155891.59 | 13.79% | | 50-100亿 | 21(21) | 313671.89 | 59673.43 | 10.23% | | 20-50亿 | 44(44) | 704573.71 | 73165.74 | 8.58 ...

Core Viewpoint - The article provides an analysis of the performance of fund managers managing over 100 billion yuan in assets, highlighting their average returns in the first half of 2025 across different fund types, including stock, mixed, and bond funds [3][4][10]. Group 1: Stock Fund Managers - There are 139 stock fund managers with a total management scale exceeding 5.21 trillion yuan, achieving an average return of 4.34% in the first half of 2025, with 76.98% of them reporting positive returns [4][5]. - The top-performing stock fund managers include Zhang Lu from Yongying Fund, who achieved a return of 32.14% with a management scale of 127.69 billion yuan [7][8]. - Other notable managers include Tian Ximeng from Fuquan Fund, with a return of 23.51% and a management scale of 536.01 billion yuan [9]. Group 2: Mixed Fund Managers - There are 68 mixed fund managers managing over 1.84 trillion yuan, with an average return of 2.20% in the first half of 2025 [10][11]. - The top mixed fund manager is Zheng Lei from Huatai-PB Fund, achieving a return of 21.69% with a management scale of 117.20 billion yuan [12][13]. - Other top performers include Wan Qiong from Bosera Fund, with a return of 12.55% and a management scale of 506.10 billion yuan [15]. Group 3: Bond Fund Managers - A total of 425 bond fund managers manage over 12.36 trillion yuan, with an average return of 1.08% in the first half of 2025 [17]. - The leading bond fund manager is Guo Jun from Bosera Fund, achieving a return of 7.59% with a management scale of 458.39 billion yuan [19][20]. - Liu Wenliang from Southern Fund follows with a return of 5.15% and a management scale of 107.26 billion yuan [22].

在这样的市场背景下， 据私募排排网数据， 有 2010只私募产品（在私募排排网有业绩展示且成立满1年）在今年6月份净值曾创下历史新高，占 在私募排排网有近1年业绩展示的私募产品的比例约为45.68%。 按产品类型来看，量化产品占 965只，非量化产品占1045只 。 按照产品策略（一级策略）来看，股票策略产品最多（主要是主观多头和量化多 头），有 1153只； 其次是多资产策略产品占272只，债券策略产品占257只，期货及衍生品策略产品占256只，组合基金产品占72只。 按公司规模来看，来自5亿以下规模私募的产品最多，有790只，占比近4成；来自百亿私募的产品有283只。 为了给读者提供一些参考， 笔者在创新高私募产品中按照产品策略分别梳理出了 "股票策略-主观多头、股票策略-量化多头、期货及衍生品策 略、多资产策略、债券策略"近一年收益居前20强的私募产品（公司规模在5亿以上）； 此外，鉴于读者对于百亿私募产品颇为关注，笔者还特 在创新高的百亿私募产品中梳理出了 "近一年收益20强"和"近三年收益20强" 。 （ 同一基金经理管理多只相同策略产品的，仅选收益最高的产 品参与排名 ） 0 1 股票 - 量化多 ...

Core Viewpoint - The performance of fund managers is crucial for investors, especially for actively managed funds, and the article highlights the top-performing fund managers in the first half of 2025 based on their returns and management scale [2][34]. Group 1: Overall Fund Manager Performance - A total of 3,358 fund managers reported their performance for the first half of 2025, with an average return of 4.89% and a median return of 0.93% [2]. - Larger fund managers tend to have lower overall returns, possibly due to a lack of index-driven market trends and a higher proportion of managers handling bond and money market funds [2][34]. Group 2: Fund Managers with Over 100 Billion Yuan - Among fund managers managing over 100 billion yuan, the average return was 2.50% with a median of 0.93%, and the threshold for the top 20 was approximately 15.60% [3][4]. - The top five fund managers in this category are: 1. Wu Yuanyi (Guangfa Fund) - 32.19% return 2. Yan Siqian (Penghua Fund) - 24.65% return 3. Zhao Bei (ICBC Credit Suisse Fund) - 23.32% return 4. Yang Dong (Guangfa Fund) - 22.50% return 5. He Qi (Huatai-PB Fund) - 20.50% return [4][5]. Group 3: Fund Managers with 50-100 Billion Yuan - For fund managers managing between 50-100 billion yuan, the average return was 4.41% with a median of 1.87%, and the threshold for the top 20 was nearly 14% [11][12]. - The top five fund managers in this category are: 1. Zheng Ning (Bank of China Fund) - 58.14% return 2. Zhang Wei (Huitianfu Fund) - 42.36% return 3. Yang Zhenshao (E Fund) - 40.25% return 4. Zhao Wei (Fortune Fund) - 36.83% return 5. Nong Bingli (Invesco Great Wall Fund) - 33.00% return [12][16]. Group 4: Fund Managers with 20-50 Billion Yuan - Fund managers in the 20-50 billion yuan range had an average return of 5.31% and a median of 3.04%, with a top 20 threshold of about 21% [19][20]. - The top five fund managers in this category are: 1. Zhou Sicong (Ping An Fund) - 57.27% return 2. Peng Chenchen (Fortune Fund) - 40.22% return 3. Jin Xiaofei (Penghua Fund) - 39.85% return 4. Sang Xiangyu (Huashan Fund) - 38.69% return 5. Hao Miao (Jia Shi Fund) - 33.12% return [20][22]. Group 5: Fund Managers with 5-20 Billion Yuan - For fund managers managing between 5-20 billion yuan, the average return was 5.93% with a median of 4.03%, and the threshold for the top 20 was approximately 24.56% [23][24]. - The top five fund managers in this category are: 1. Zhang Jintao (Huabao Fund) - 41.93% return 2. Zhao Xiaoyan (Hengyue Fund) - 39.10% return 3. Chi Chenshen (Anxin Fund) - 36.26% return 4. Shan Lin (Yongying Fund) - 36.13% return 5. Zhang Jialu (Ruiyuan Fund) - 33.15% return [24][28].

本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 券商资管产品是由证券公司或其资管子公司作为管理人，依照资产管理合同约定的方式、条件及 限制，对客户资产进行投资管理的金融工具。 券商的资产管理产品主要分为 集合资管计划、定向资管计划、专项资管计划 。而我们常说的券 商资管产品一般指代的是券商集合资管计划。券商集合资管计划 根据投资标的可以分为 股票型 、 债券型 、混合 型 、 FOF 、 QDII、货币市场型 、 另类投资 等。 根据中国证券投资基金业协会数据，截至2025年一季度末（最新数据）， 券商运行的资管产品 （集合资管计划）共有 10210只，产品总规模约为28215亿元。 其中， "集合资管计划"总规模超100亿元的券商（或资管公司）共有31家。 中信证券、国泰海 通、中金公司、中银证券、广发资管、广发证券、招商证券、中信建投证券、国金证券、国金资 管、首创证券等 11家券商的"集合资管计划"规模均在千亿元级别。中信证券以3432亿元的管理 规模位列第1。 0 1 股票型券商资管产品在近一年领跑！ 那么券商资管产品（在此仅包括"集合资管计划"）的最新业绩如何呢？ 根据Choice数 ...

本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 近日，创新药再迎重磅政策利好，相关概念股近 1周涨幅领衔各大题材。 截至7月4日，塞力医疗 实现四连板，广生堂实现两连板。消息面上，6月30日，国家医保局、国家卫健委联合印发《支 持创新药高质量发展的若干措施》，从研发、准入、支付、使用到国际化布局推出16项针对性举 措， 首次系统性构建覆盖创新药全生命周期的政策支持体系 。 注：以上内容来自方正证券《多个新政策出台支持创新药发展，商业保险目录落地打开支付空间 》(2025.07.3)。引用内容仅 为研究之目的，如需删除请及时联系我司处理。 有市场分析指，中国创新药产业已进入 "政策驱动型增长"新阶段。 根据国家药监局数据， 2025 年上半年医保基金累计支付谈判药品4100亿元（较2024年全年1000亿元增长310%） ，直接撬动 6000亿销售规模。从创新药审批数量来看，2024年5年1类创新药获批数量达48种，是2018年的5 倍多。 2025年上半年，获批的1类创新药数量已经达到近40种，为2024年全年的83.33%。 除了政策面的利好，创新药今年以来还迎来了基本面、技术层面、国际化等 ...